REFERENCES
1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15:5-13.
3. Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103.
4. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018;15:599-616.
5. Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, et al. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol 2018;48:103-14.
6. Abou-Alfa GK, Huitzil-Melendez FD, O’Reilly EM, Saltz LB. Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2008;2:64-70.
8. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223-38.
9. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; Diseases AAftSoL. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328-43.
10. Liver EAFTSOT. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3-22.
11. Crawford DHG. Hereditary hemochromatosis types 1, 2, and 3. Clin Liver Dis (Hoboken) 2014;3:96-7.
12. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4:183-98.
13. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
14. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008;149:270-2.
15. Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis 2007;39:140-7.
16. Gan EK, Powell LW, Olynyk JK. Natural history and management of HFE-hemochromatosis. Semin Liver Dis 2011;31:293-301.
17. Golfeyz S, Lewis S, Weisberg IS. Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI. Expert Rev Gastroenterol Hepatol 2018;12:767-78.
18. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.
19. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
20. de Campos WN, Massaro JD, Cançado ELR, Wiezel CEV, Simões AL, et al. Comprehensive analysis of. World J Hepatol 2019;11:186-98.
21. Barton JC, Acton RT. HLA-A and -B alleles and haplotypes in hemochromatosis probands with HFE C282Y homozygosity in central Alabama. BMC Med Genet 2002;3:9.
23. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008;358:221-30.
24. Trifa AP, Popp RA, Militaru MS, Farcaş MF, Crişan TO, et al. HFE gene C282Y, H63D and S65C mutations frequency in the Transylvania region, Romania. J Gastrointestin Liver Dis 2012;21:177-80.
25. Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998;95:1472-7.
26. Giannetti AM, Björkman PJ. HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface. J Biol Chem 2004;279:25866-75.
27. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 2008;7:205-14.
28. Vujić Spasić M, Kiss J, Herrmann T, Galy B, Martinache S, et al. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab 2008;7:173-8.
30. Zhang AS, Enns CA. Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 2009:207-14.
33. Beutler E, Gelbart T, West C, Lee P, Adams M, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996;22:187-94.
34. Mura C, Raguenes O, Férec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999;93:2502-5.
35. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999;130:953-62.
36. Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009;50:94-101.
37. Walsh A, Dixon JL, Ramm GA, Hewett DG, Lincoln DJ, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006;4:1403-10.
38. Cardoso CS, de Sousa M. HFE, the MHC and hemochromatosis: paradigm for an extended function for MHC class I. Tissue Antigens 2003;61:263-75.
39. Torres FR, Souza-Neiras WC, D’Almeida Couto AA, D’Almeida Couto VS, Cavasini CE, et al. Frequency of the HFE C282Y and H63D polymorphisms in Brazilian malaria patients and blood donors from the Amazon region. Genet Mol Res 2008;7:60-4.
40. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-9.
41. Kew MD. Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: occurrence in noncirrhotic patients. Hepatology 1990;11:1086-7.
42. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-41.
43. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001;33:647-51.
44. Haddow JE, Palomaki GE, McClain M, Craig W. Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen 2003;10:11-3.
45. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160-2.
46. Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis. Observations in 163 patients. Ann N Y Acad Sci 1988;526:245-57.
47. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998;129:946-53.
48. Cauza E, Peck-Radosavljevic M, Ulrich-Pur H, Datz C, Gschwantler M, et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 2003;98:442-7.
49. Ezzikouri S, El Feydi AE, El Kihal L, Afifi R, Benazzouz M, et al. Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population. Arch Med Res 2008;39:236-41.
50. Fargion S, Stazi MA, Fracanzani AL, Mattioli M, Sampietro M, et al. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Blood Cells Mol Dis 2001;27:505-11.
51. Hellerbrand C, Pöppl A, Hartmann A, Schölmerich J, Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 2003;1:279-84.
52. Lauret E, Rodríguez M, González S, Linares A, López-Vázquez A, et al. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 2002;97:1016-21.
53. Nahon P, Sutton A, Rufat P, Ziol M, Thabut G, et al. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 2008;134:102-10.
54. Pirisi M, Toniutto P, Uzzau A, Fabris C, Avellini C, et al. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer 2000;89:297-302.
55. Ropero P, Briceño O, López-Alonso G, Agúndez JA, González Fernández FA, et al. The H63D mutation in the HFE gene is related to the risk of hepatocellular carcinoma. Rev Esp Enferm Dig 2007;99:376-81. (in Spanish)
56. Shi WJ, Chen H, Zhou B, Cheng J. Association of mutations of HFE gene and hepatocellular carcinoma following chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2005;13:682-4. (in Chinese)
57. Willis G, Wimperis JZ, Lonsdale R, Fellows IW, Watson MA, et al. Incidence of liver disease in people with HFE mutations. Gut 2000;46:401-4.
58. Willis G, Wimperis JZ, Lonsdale R, Jennings BA. Haemochromatosis gene mutation in hepatocellular cancer. Lancet 1997;350:565-6.
59. Sánchez-Luna SA, Brown KE. Clinical burden of liver disease from hemochromatosis at an academic medical center. Hepatol Commun 2017;1:453-9.
60. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 2007;46:1071-80.
61. Ye Q, Qian BX, Yin WL, Wang FM, Han T. Association between the HFE C282Y, H63D polymorphisms and the risks of non-alcoholic fatty liver disease, liver cirrhosis and hepatocellular carcinoma: an updated systematic review and meta-analysis of 5,758 cases and 14,741 controls. PLoS One 2016;11:e0163423.
62. Asberg A, Hveem K, Thorstensen K, Ellekjter E, Kannelønning K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001;36:1108-15.
63. Gharib AF, Karam RA, Pasha HF, Radwan MI, Elsawy WH. Polymorphisms of hemochromatosis, and alpha-1 antitrypsin genes in Egyptian HCV patients with and without hepatocellular carcinoma. Gene 2011;489:98-102.
64. Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin North Am 2005;89:391-409.
65. Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, et al. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65.
66. Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2010;24:725-34.
67. Bradbear RA, Bain C, Siskind V, Schofield FD, Webb S, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst 1985;75:81-4.
68. Blanc JF, De Ledinghen V, Bernard PH, de Verneuil H, Winnock M, et al. Increased incidence of HFE C282Y mutations in patients with iron overload and hepatocellular carcinoma developed in non-cirrhotic liver. J Hepatol 2000;32:805-11.
69. Hiatt T, Trotter JF, Kam I. Hepatocellular carcinoma in a noncirrhotic patient with hereditary hemochromatosis. Am J Med Sci 2007;334:228-30.
70. Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, et al. Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology 2006;219:41-52.
71. Willis G, Bardsley V, Fellows IW, Lonsdale R, Wimperis JZ, et al. Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. BMC Gastroenterol 2005;5:17.
72. Fracanzani AL, Fargion S, Stazi MA, Valenti L, Amoroso P, et al. Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. Blood Cells Mol Dis 2005;35:27-32.
73. Nowak A, Giger RS, Krayenbuehl PA. Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: a prospective longitudinal observational study. Medicine (Baltimore) 2018;97:e12886.
74. Boige V, Castéra L, de Roux N, Ganne-Carrié N, Ducot B, et al. Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 2003;52:1178-81.
75. Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res 2010;29:18.
76. Campo S, Restuccia T, Villari D, Raffa G, Cucinotta D, et al. Analysis of haemochromatosis gene mutations in a population from the Mediterranean Basin. Liver 2001;21:233-6.
77. Constantine CC, Gurrin LC, McLaren CE, Bahlo M, Anderson GJ, et al. SNP selection for genes of iron metabolism in a study of genetic modifiers of hemochromatosis. BMC Med Genet 2008;9:18.
78. Racchi O, Mangerini R, Rapezzi D, Gaetani GF, Nobile MT, et al. Mutations of the HFE gene and the risk of hepatocellular carcinoma. Blood Cells Mol Dis 1999;25:350-3.
80. Shen Y, Li X, Zhao B, Xue Y, Wang S, et al. Iron metabolism gene expression and prognostic features of hepatocellular carcinoma. J Cell Biochem 2018;119:9178-204.
82. Worthen CA, Enns CA. The role of hepatic transferrin receptor 2 in the regulation of iron homeostasis in the body. Front Pharmacol 2014;5:34.
84. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
85. West AP, Bennett MJ, Sellers VM, Andrews NC, Enns CA, et al. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatosis protein HFE. J Biol Chem 2000;275:38135-8.
86. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, et al. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 2006;108:1402-5.
87. Wu XG, Wang Y, Wu Q, Cheng WH, Liu W, et al. HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression. Blood 2014;124:1335-43.
88. Gao J, Chen J, Kramer M, Tsukamoto H, Zhang AS, et al. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab 2009;9:217-27.
89. Zacharski LR, Ornstein DL, Woloshin S, Schwartz LM. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J 2000;140:98-104.
90. Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS. Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J Pathol 2006;208:82-90.
91. Ioannou GN, Kowdley KV. Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen? Clin Gastroenterol Hepatol 2003;1:246-8.
92. Ramm GA, Crawford DH, Powell LW, Walker NI, Fletcher LM, et al. Hepatic stellate cell activation in genetic haemochromatosis. Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J Hepatol 1997;26:584-92.
93. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007;6:1982-94.
94. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009;100:9-16.
95. Fargion S, Valenti L, Fracanzani AL. Role of iron in hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2014;3:108-10.
96. Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer 2017;123:751-8.
97. Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One 2013;8:e59459.
98. Miyanishi K, Tanaka S, Sakamoto H, Kato J. The role of iron in hepatic inflammation and hepatocellular carcinoma. Free Radic Biol Med 2019;133:200-5.
99. Muto Y, Moroishi T, Ichihara K, Nishiyama M, Shimizu H, et al. Disruption of FBXL5-mediated cellular iron homeostasis promotes liver carcinogenesis. J Exp Med 2019;216:950-65.
100. Hussain SP, Hollstein MH, Harris CC. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann N Y Acad Sci 2000;919:79-85.
101. Ichiba M, Maeta Y, Mukoyama T, Saeki T, Yasui S, et al. Expression of 8-hydroxy-2’-deoxyguanosine in chronic liver disease and hepatocellular carcinoma. Liver Int 2003;23:338-45.
102. Valerio LG, Petersen DR. Characterization of hepatic iron overload following dietary administration of dicyclopentadienyl iron (Ferrocene) to mice: cellular, biochemical, and molecular aspects. Exp Mol Pathol 2000;68:1-12.
103. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127:S79-86.
104. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 2005;100:837-41.
105. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277-87.
106. Asare GA, Bronz M, Naidoo V, Kew MC. Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis. Toxicology 2008;254:11-8.
107. Nahon P, Sutton A, Pessayre D, Rufat P, Charnaux N, et al. Do genetic variations in antioxidant enzymes influence the course of hereditary hemochromatosis? Antioxid Redox Signal 2011;15:31-8.
108. Houglum K, Bedossa P, Chojkier M. TGF-beta and collagen-alpha 1 (I) gene expression are increased in hepatic acinar zone 1 of rats with iron overload. Am J Physiol 1994;267:G908-13.
109. Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta 2009;1790:663-70.
110. Hann HW, Stahlhut MW, Hann CL. Effect of iron and desferoxamine on cell growth and in vitro ferritin synthesis in human hepatoma cell lines. Hepatology 1990;11:566-9.
111. Shen Y, Li X, Su Y, Badshah SA, Zhang B, et al. Downregulation contributes to aggressive hepatocellular carcinoma via mechanism mediated by cyclin4-dependent kinase-1/STAT3 pathway. Diagnostics (Basel) 2019;9.
112. Djeha A, Brock JH. Effect of transferrin, lactoferrin and chelated iron on human T-lymphocytes. Br J Haematol 1992;80:235-41.
113. Green R, Esparza I, Schreiber R. Iron inhibits the nonspecific tumoricidal activity of macrophages. A possible contributory mechanism for neoplasia in hemochromatosis. Ann N Y Acad Sci 1988;526:301-9.
114. Cozma A, Fodor A, Vulturar R, Sitar-Tăut AV, Orăşan OH, et al. DNA methylation and micro-RNAs: the most recent and relevant biomarkers in the early diagnosis of hepatocellular carcinoma. Medicina (Kaunas) 2019;55.
115. Lehmann U, Wingen LU, Brakensiek K, Wedemeyer H, Becker T, et al. Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet 2007;16:1335-42.
116. Adams P, Altes A, Brissot P, Butzeck B, Cabantchik I, et al. Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. Hepatol Int 2018;12:83-6.
117. Loréal O, Cavey T, Robin F, Kenawi M, Guggenbuhl P, et al. Iron as a therapeutic target in HFE-related hemochromatosis: usual and novel aspects. Pharmaceuticals (Basel) 2018;11.
118. Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology 2010;52:1671-779.
119. Tauchenová L, Křížová B, Kubánek M, Fraňková S, Melenovský V, et al. Successful treatment of iron-overload cardiomyopathy in hereditary hemochromatosis with deferoxamine and deferiprone. Can J Cardiol 2016;32:1574.e1-e3.
120. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006;103:14901-6.
121. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86:4295-306.
122. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, et al. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004;22:1553-63.
123. Fung E, Sugianto P, Hsu J, Damoiseaux R, Ganz T, et al. High-throughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol 2013;83:681-90.
124. MacPhail AP, Mandishona EM, Bloom PD, Paterson AC, Rouault TA, et al. Measurements of iron status and survival in African iron overload. S Afr Med J 1999;89:966-72.
125. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998;27:1563-6.
126. Turlin B, Juguet F, Moirand R, Le Quilleuc D, Loréal O, et al. Increased liver iron stores in patients with hepatocellular carcinoma developed on a noncirrhotic liver. Hepatology 1995;22:446-50.
